Martin Wichmann

Carl Neuberg Str. 1
Hannover, NI 30625, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy.

Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy.

Journal: Cancers

Published: August 14, 2025

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.

A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents.

Journal: Leukemia

Published: May 14, 2024

Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation.

Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation.

Journal: Blood

Published: September 28, 2023

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML.

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML.

Journal: Cancers

Published: June 22, 2023

Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Journal: Haematologica

Published: February 08, 2023

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.

Journal: Annals of hematology

Published: August 24, 2022

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.

Journal: Blood advances

Published: January 25, 2021

FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.

FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.

Journal: British journal of haematology

Published: June 28, 2019

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Journal: Blood

Published: February 01, 2018

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.

Journal: Annals of hematology

Published: May 21, 2017

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Journal: Leukemia

Published: July 20, 2016

Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.

Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.

Journal: Blood

Published: December 17, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026